Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label, Single-Arm, Phase 1/2 Study Evaluating the Safety and Efficacy of Ponatinib for the Treatment of Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors in Pediatric Participants

Next Previous
Search
Trial Profile

An Open-Label, Single-Arm, Phase 1/2 Study Evaluating the Safety and Efficacy of Ponatinib for the Treatment of Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors in Pediatric Participants

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 27 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ponatinib (Primary)
  • Indications Acute myeloid leukaemia; Chronic myeloid leukaemia; Leukaemia; Lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma; Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Incyte Biosciences International

    • Most Recent Events

    • 13 Aug 2024 Planned End Date changed from 4 Jan 2025 to 30 Jan 2026.
    • 13 Aug 2024 Planned primary completion date changed from 7 Dec 2024 to 30 Jan 2026.
    • 12 Sep 2023 Planned number of patients changed from 60 to 85.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top